Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Drug sensitivity of clinical isolates of Mycobacterium tuberculosis and its association with bacterial genotype in the Somali region, Eastern Ethiopia
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4651917
Author(s) Worku, G.; Gumi, B.; Girma, M.; Mohammedbirhan, B.; Diriba, G.; Seid, G.; Getu, M.; Amare, M.; Sinshaw, W.; Ashagre, W.; Tschopp, R.; Carruth, L.; Ameni, G.
Author(s) at UniBasel Tschopp, Rea
Year 2022
Title Drug sensitivity of clinical isolates of Mycobacterium tuberculosis and its association with bacterial genotype in the Somali region, Eastern Ethiopia
Journal Frontiers in Public Health
Volume 10
Pages / Article-Number 942618
Keywords Somali region of Ethiopia; bacterial genotype; drug sensitivity; mycobacterium tuberculosis; performance of Xpert; commercial or financial relationships that could be construed as a potential; conflict of interest.
Mesh terms Antitubercular Agents, therapeutic use; Drug Resistance; Ethiopia, epidemiology; Genotype; Humans; Mycobacterium tuberculosis, genetics; Rifampin, pharmacology; Somalia; Tuberculosis, Multidrug-Resistant, microbiology
Abstract Background: Drug resistance is becoming a major bottleneck for tuberculosis (TB) control programs in countries with high TB burdens. Although several studies were conducted on the drug sensitivity of Mycobacterium tuberculosis (M. tuberculosis) in central Ethiopia, there is a lack of data on the drug sensitivity of M. tuberculosis in the peripheral regions of the country including in the Somali region. Therefore, the objective of this study was to evaluate the drug sensitivity of M. tuberculosis and its association with bacterial genotype and evaluate the performance of Xpert MTB/RIF (Xpert) in detecting resistance to rifampicin (RIF). Methods: A total of 302 M. tuberculosis were tested using the BD BACTEC-Mycobacteria Growth Indicator Tube 960 (MGIT 960) system for their drug sensitivity to the first-line anti-TB drugs. Besides, the drug sensitivity of 10 multidrug-resistant (MDR) M. tuberculosis isolates was evaluated for the second-line anti-TB drugs. Additionally, 177 of the 302 isolates were tested for genotypic drug resistance using Xpert. Chi-square and Fisher's exact tests were used for the evaluation of the association between variables and drug sensitivity. Results: The overall prevalence of resistance to at least one drug was 11.6% (95% CI: 7.9-15.2%), while the prevalence of MDR was 3.3% (95% CI: 1.3-5.3%). Two of the 10 MDR isolates were resistant to capreomycin. The spoligotype Shared International Type (SIT) 149 was significantly associated with either monoresistance or MDR (p < 0.05). Of the 177 isolates tested by Xpert, 6.2% (11/177) were RIF-resistant. Discordant between Xpert and MGIT 960 was observed in one isolate and linked with probe-binding delay (DeltaCT max = 5.8). The sensitivity and specificity of the Xpert assay were 100 and 99.4%, respectively, while its positive and negative predictive values were 90.9 and 100%, respectively. Conclusion: The magnitude of MDR M. tuberculosis in the Somali region of Ethiopia was higher than the national prevalence of MDR-TB warranting the strengthening of the TB control program in the Somali region. Besides, drug resistance was associated with SIT 149 spoligotype (genotype). The Xpert assay was observed to have high sensitivity and specificity in detecting RIF-resistant M. tuberculosis, which is encouraging for its application widely.
Publisher Frontiers Media
ISSN/ISBN 2296-2565
edoc-URL https://edoc.unibas.ch/91008/
Full Text on edoc Available
Digital Object Identifier DOI 10.3389/fpubh.2022.942618
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/36062084
ISI-Number WOS:000848135200001
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.328 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
19/06/2024